VEGF-165 Polyclonal Antibody, PeproTech®, Invitrogen™

Description

• AA Sequence of recombinant protein: APMAEGGGQN HHEVVKFMDV YQRSYCHPIE TLVDIFQEYP DEIEYIFKPS CVPLMRCGGC CNDEGLECVP TEESNITMQI MRIKPHQGQH IGEMSFLQHN KCECRPKKDR ARQENPCGPC SERRKHLFVQ DPQTCKCSCK NTDSRCKARQ LELNERTCRC DKPRR
• Preparation: Produced from sera of rabbits immunized with highly pure Recombinant Human VEGF 165
• Anti-Human VEGF 165-specific antibody was purified by affinity chromatography employing an immobilized Human VEGF 165 matrix
• Sandwich ELISA: To detect Human VEGF 165 by sandwich ELISA (using 100 μL/well antibody solution) a concentration of 0.5-2.0 μg/mL of this antibody is required
• This antigen affinity purified antibody, in conjunction with PeproTech Biotinylated Anti-Human VEGF 165 (500-P10Bt) as a detection antibody, allows the detection of at least 0.2-0.4 ng/well of Recombinant Human VEGF 165
• Western Blot: To detect Human VEGF 165 by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 μg/mL
• Used in conjunction with compatible secondary reagents the detection limit for Recombinant Human VEGF 165 is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions
• The vascular endothelial growth factor (VEGF) family currently includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and PIGF
• VEGF and its receptor system have been shown to be the fundamental regulators in the cell signaling of angiogenesis
• Most tumors have the absolute requirement of angiogenesis and VEGF has been described as the most potent angiogenic cytokine linked to this process
• To date 5 different isoforms of VEGF have been described
• These isoforms are generated as the result of alternative splicing from a single VEGF gene
• These various isoforms have been shown to bind to two tyrosine-kinase receptors flt-1 (VEGFR-1) and flk-1/KDR (VEGFR-2), which have been found to be expressed almost exclusively on endothelial cells.